2026-01-18 - Analysis Report
**Company Overview**
Rocket Lab USA Inc is a leader in the private aerospace company.

**Return Analysis**
* Cumulative return of review stock (RKLB): 612.11%
* Cumulative return of comparison stock (S&P 500, VOO): 49.01%
* Divergence (degree of divergence): 563.10
* Relative divergence: 100.00%

The review stock has significantly outperformed the comparison stock, with a large divergence in cumulative return.

**Alpha, Beta Analysis**
* CAGR: 
  * 2021-2023: 3.0%
  * 2022-2024: 210.0%
  * 2023-2025: 443.0%
* MDD: 
  * 2021-2023: 48.2%
  * 2022-2024: 40.8%
  * 2023-2025: 47.3%
* Alpha: 
  * 2021-2023: 3.0%
  * 2022-2024: 190.0%
  * 2023-2025: 380.0%
* Beta:
  * 2021-2023: 1.8
  * 2022-2024: 2.0
  * 2023-2025: 2.2
* Market Capitalization:
  * 2021-2023: $3.0B
  * 2022-2024: $13.6B
  * 2023-2025: $37.3B

The review stock has shown significant growth in CAGR, especially in the 2022-2024 period. The Alpha values suggest the review stock has outperformed the market, while the Beta values indicate a moderate level of volatility.

**Recent Stock Price Fluctuations**
* Close: $96.30
* Last-market: $96.3 (price) / $90.76 (previous close) / $6.1 (change)
* 5-day SMA: $90.67
* 20-day SMA: $79.44
* 60-day SMA: $61.21

The recent sharp rebound from a low previous close suggests a positive trend.

**RSI, PPO Analysis**
* RSI: 83.13
* PPO: 0.63
* Market Risk Indicator (MRI): 0.80
* Hybrid Signal: Buy
* Risk Level: Medium
* Recent (20 days) relative divergence change: 1.80 (+): improving
* 7-day Rank change: -9 (-): rank down
* 7-day Dynamic Expected Return change: 0.00 (0): flat

The RSI and PPO indicators suggest the review stock is overbought, while the MRI indicates a medium risk level. The hybrid signal is Buy, and the risk level is considered medium.

**Expected Return**
* Expected Return: 5.70%
* Expected excess return compared to S&P 500 if invested long-term (more than 2 years): 5.70%

**Recent News & Significant Events**
* [2026-01-16] Upgrade, Defense Contract Prompt Rallies For Two Space Stocks - Investor's Business Daily (news.google.com)
* [2026-01-15] Rocket Lab Enters A Different League (NASDAQ:RKLB) - Seeking Alpha (news.google.com)
* [2026-01-14] Why Rocket Lab (RKLB) Stock Is Up Today - Yahoo Finance (news.google.com)
* [2026-01-14] Rocket Lab: Neutron Euphoria Has Pushed The Stock Into Sell Territory (Rating Downgrade) - Seeking Alpha (news.google.com)
* [2026-01-15] Rocket Lab Stock Gets A Rare Downgradeâ€”Here's Why - Benzinga (news.google.com)
* [2026-01-15] Is Rocket Lab Stock a Buy After Its Massive Run - The Motley Fool (news.google.com)

The recent news suggests a positive sentiment towards the review stock, with potential upgrades and defense contracts boosting its value.

**Analyst Opinions**
* Analyst Consensus:
  * Key: Buy
  * Mean (1=StrongBuy~5=Sell): 1.80 (~Buy)
  * Opinions: 12
  * Target Price (avg/high/low): 78.96 / 105.00 / 55.00

The analyst consensus is to buy the review stock, with a target price range.

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-10 | -0.03 | $0.16 B |
| 2025-08-07 | -0.13 | $0.14 B |
| 2025-05-08 | -0.12 | $0.12 B |
| 2024-11-12 | -0.1 | $0.10 B |
| 2025-11-10 | -0.1 | $0.10 B |

The review stock has reported negative EPS in recent quarters, while revenue remains relatively stable.

**Financial Information**
**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $0.16B | 36.96% |
| 2025-06-30 | $0.14B | 32.10% |
| 2025-03-31 | $0.12B | 28.76% |
| 2024-12-31 | $0.13B | 27.81% |
| 2024-09-30 | $0.10B | 26.71% |

**Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $1.28B | -1.43% |
| 2025-06-30 | $0.69B | -9.65% |
| 2025-03-31 | $0.43B | -14.05% |
| 2024-12-31 | $0.38B | -13.69% |
| 2024-09-30 | $0.42B | -12.37% |

The review stock has reported increasing revenue and a declining profit margin in recent quarters, while equity has been decreasing.

**Comprehensive Analysis**
The review stock has shown significant growth in CAGR, especially in the 2022-2024 period, and has outperformed the market in terms of Alpha. The recent sharp rebound from a low previous close suggests a positive trend. The RSI and PPO indicators suggest the review stock is overbought, while the MRI indicates a medium risk level. The hybrid signal is Buy, and the risk level is considered medium. The analyst consensus is to buy the review stock, with a target price range. However, the review stock has reported negative EPS in recent quarters, while revenue remains relatively stable.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.